Global Nonalcoholic Steatohepatitis (NASH) Market Size, Status and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 97

Report ID: 19731

Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.
At present, vitamin E & pioglitazone segment dominates the non-alcoholic steatohepatitis (NASH) market, due to efficacy.
Asia-Pacific presents lucrative opportunities for the key players operating in the non-alcoholic steatohepatitis (NASH) market. Some factors such as growth in diagnostic techniques, rapid rise in prevalence NASH, growth in economies, and increase in demand for NASH therapeutics drive the market growth in Asia-Pacific.
In 2018, the global Nonalcoholic Steatohepatitis (NASH) market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Nonalcoholic Steatohepatitis (NASH) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Nonalcoholic Steatohepatitis (NASH) development in United States, Europe and China.

The key players covered in this study
Tobira Therapeutics
Cadila Healthcare
Conatus Pharmaceuticals
Galmed Pharmaceuticals
Gemphire Therapeutics
Genfit
Gilead Sciences
Intercept Pharmaceuticals
Novartis International
Shire

Market segment by Type, the product can be split into
Vitamin E & Pioglitazone
Ocaliva
Elafibranor
Selonsertib & Cenicriviroc

Market segment by Application, split into
Hospital Pharmacy
Online Provider
Retail Pharmacy  

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Nonalcoholic Steatohepatitis (NASH) status, future forecast, growth opportunity, key market and key players.
To present the Nonalcoholic Steatohepatitis (NASH) development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Nonalcoholic Steatohepatitis (NASH) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type (2014-2025)
1.4.2 Vitamin E & Pioglitazone
1.4.3 Ocaliva
1.4.4 Elafibranor
1.4.5 Selonsertib & Cenicriviroc
1.5 Market by Application
1.5.1 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2014-2025)
1.5.2 Hospital Pharmacy
1.5.3 Online Provider
1.5.4 Retail Pharmacy  
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Nonalcoholic Steatohepatitis (NASH) Market Size
2.2 Nonalcoholic Steatohepatitis (NASH) Growth Trends by Regions
2.2.1 Nonalcoholic Steatohepatitis (NASH) Market Size by Regions (2014-2025)
2.2.2 Nonalcoholic Steatohepatitis (NASH) Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Nonalcoholic Steatohepatitis (NASH) Market Size by Manufacturers
3.1.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue by Manufacturers (2014-2019)
3.1.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio (CR5 and HHI)
3.2 Nonalcoholic Steatohepatitis (NASH) Key Players Head office and Area Served
3.3 Key Players Nonalcoholic Steatohepatitis (NASH) Product/Solution/Service
3.4 Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2014-2019)
4.2 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2014-2019)

5 United States
5.1 United States Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
5.2 Nonalcoholic Steatohepatitis (NASH) Key Players in United States
5.3 United States Nonalcoholic Steatohepatitis (NASH) Market Size by Type
5.4 United States Nonalcoholic Steatohepatitis (NASH) Market Size by Application

6 Europe
6.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
6.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Europe
6.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type
6.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application

7 China
7.1 China Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
7.2 Nonalcoholic Steatohepatitis (NASH) Key Players in China
7.3 China Nonalcoholic Steatohepatitis (NASH) Market Size by Type
7.4 China Nonalcoholic Steatohepatitis (NASH) Market Size by Application

8 Japan
8.1 Japan Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
8.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Japan
8.3 Japan Nonalcoholic Steatohepatitis (NASH) Market Size by Type
8.4 Japan Nonalcoholic Steatohepatitis (NASH) Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
9.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Southeast Asia
9.3 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type
9.4 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application

10 India
10.1 India Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
10.2 Nonalcoholic Steatohepatitis (NASH) Key Players in India
10.3 India Nonalcoholic Steatohepatitis (NASH) Market Size by Type
10.4 India Nonalcoholic Steatohepatitis (NASH) Market Size by Application

11 Central & South America
11.1 Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
11.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Central & South America
11.3 Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
11.4 Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size by Application

12 International Players Profiles
12.1 Tobira Therapeutics
12.1.1 Tobira Therapeutics Company Details
12.1.2 Company Description and Business Overview
12.1.3 Nonalcoholic Steatohepatitis (NASH) Introduction
12.1.4 Tobira Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
12.1.5 Tobira Therapeutics Recent Development
12.2 Cadila Healthcare
12.2.1 Cadila Healthcare Company Details
12.2.2 Company Description and Business Overview
12.2.3 Nonalcoholic Steatohepatitis (NASH) Introduction
12.2.4 Cadila Healthcare Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
12.2.5 Cadila Healthcare Recent Development
12.3 Conatus Pharmaceuticals
12.3.1 Conatus Pharmaceuticals Company Details
12.3.2 Company Description and Business Overview
12.3.3 Nonalcoholic Steatohepatitis (NASH) Introduction
12.3.4 Conatus Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
12.3.5 Conatus Pharmaceuticals Recent Development
12.4 Galmed Pharmaceuticals
12.4.1 Galmed Pharmaceuticals Company Details
12.4.2 Company Description and Business Overview
12.4.3 Nonalcoholic Steatohepatitis (NASH) Introduction
12.4.4 Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
12.4.5 Galmed Pharmaceuticals Recent Development
12.5 Gemphire Therapeutics
12.5.1 Gemphire Therapeutics Company Details
12.5.2 Company Description and Business Overview
12.5.3 Nonalcoholic Steatohepatitis (NASH) Introduction
12.5.4 Gemphire Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
12.5.5 Gemphire Therapeutics Recent Development
12.6 Genfit
12.6.1 Genfit Company Details
12.6.2 Company Description and Business Overview
12.6.3 Nonalcoholic Steatohepatitis (NASH) Introduction
12.6.4 Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
12.6.5 Genfit Recent Development
12.7 Gilead Sciences
12.7.1 Gilead Sciences Company Details
12.7.2 Company Description and Business Overview
12.7.3 Nonalcoholic Steatohepatitis (NASH) Introduction
12.7.4 Gilead Sciences Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
12.7.5 Gilead Sciences Recent Development
12.8 Intercept Pharmaceuticals
12.8.1 Intercept Pharmaceuticals Company Details
12.8.2 Company Description and Business Overview
12.8.3 Nonalcoholic Steatohepatitis (NASH) Introduction
12.8.4 Intercept Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
12.8.5 Intercept Pharmaceuticals Recent Development
12.9 Novartis International
12.9.1 Novartis International Company Details
12.9.2 Company Description and Business Overview
12.9.3 Nonalcoholic Steatohepatitis (NASH) Introduction
12.9.4 Novartis International Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
12.9.5 Novartis International Recent Development
12.10 Shire
12.10.1 Shire Company Details
12.10.2 Company Description and Business Overview
12.10.3 Nonalcoholic Steatohepatitis (NASH) Introduction
12.10.4 Shire Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
12.10.5 Shire Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details